Table 2.
Astrogliosis in rodent HD models.
| Toxic Models | Strain | Dose/Day |
Astrogliosis/
Brain Region |
Age or
Weight |
Refs. |
|---|---|---|---|---|---|
| Rats+QA | Wistar Sprague-Dawley |
75 nmol/µl c 50 µg/µl c |
+/Str +/Str |
1 m 1 m |
[68] [72] |
| Mice+QA | C129SvEv | 50 nmol/µl c | +/Str | 1 m | [69] |
| Rats+3NP | Sprague-Dawley Sprague-Dawley Sprague-Dawley Wistar Wistar |
7.5 mg/kg a 25 mg/kg a 60 mg/kg a 15 mg/kg b 10 mg/kg a |
+/Str +/Str +/Str +/Str +/Str |
3 m 250-280 g 3 m 250-300 g 200-250 g |
[105] [106] [107] [108] [109] |
| Mice+3NP | C57BL/6 C57BL/6J |
50 mg/kg a 15 mg/kg a |
+/Str +/Str, -/Cx |
4 m 18-22 g |
[110] [111] |
| Transgenic Mice |
Transgene/
promoter |
CAG repeats |
Astrogliosis/
brain region |
Age | Refs. |
| R6/1 | Human exon 1/ human |
116 | +/Cx, -/Str -/Str |
4, 6 m 9 m |
[112] [113] |
| R6/2 | Human exon1/ human |
144- variable |
-/Str +/Str |
1-3 m 3m |
[84], [113] [85] |
| N171-82Q | Human 171aa/ murine prion |
82 | +/Str +/Str, +/Cx |
4 m 4m |
[113] [114] |
| HD89 | Full length Htt/ CMV |
89 | +/Str, +/Cx | 6-12 m | [96] |
| YAC128 | Full length Htt/ human |
128 | +/Cx, -/Str -/Str |
15, 24 m 12 m |
[115] [116] |
| BACHD | Full length Htt/ human |
97 | -/Str | 12 m | [117] |
| BAC-225Q | Full length Htt /mouse |
225 | -/Str +/Str |
6 m 12 m |
[95] |
| Knock-in Mice | |||||
| HdhQ111 | Human exon 1/ mouse |
111 | +/Str | 24 m | [120] |
| Hdh(CAG)150 | Murine exon 1/ mouse |
150 | +/Str -/Str -/Str |
14 m 5-6 m 5-24 m |
[101] [113] [121] |
| Hdh200 | Murine exon 1/ mouse |
200 | +/Str, +/Cx | 40 and 80 w | [118] |
| zQ175 | Human-murine exon 1/ mouse |
188 | +/Str, +/Cx +/Str |
49-53 w 12 m |
[119] [122] |
Str: striatum, Cx: cerebral cortex, m: months, w: weeks, a: intraperitoneal, b: subcutaneous, c: intrastriatal.